In Japan, evaluations for tumor markers of pancreatic cancer such as carcinoembryonic antigen (CEA), CA19-9, Span-1, and DUPAN2, are covered by insurance. The gene discussed is CEACAM5; the disease is familial pancreatic carcinoma.